The impact of received dose intensity on the outcome of advanced ovarian cancer

This publication has 16 references indexed in Scilit:

• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
  BMJ, 1991
• Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
  Journal of Clinical Oncology, 1991
• Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
  Journal of Clinical Oncology, 1991
• Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer
  Cancer Chemotherapy and Pharmacology, 1990
• Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look
  Gynecologic Oncology, 1990
• Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.
  Journal of Clinical Oncology, 1989
• Carboplatin (JM 8), Adriamycin and Cyclophosphamide (JAC) in Advanced Ovarian Carcinoma: A Pilot Study
  Tumori Journal, 1988
• Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology
  Cancer, 1984
• USE OF HIGH DOSE CIS-DICHLORODIAMMINE PLATINUM (II) (NSC-119875)+ FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY
  BJOG: An International Journal of Obstetrics and Gynaecology, 1981
• High-dose platinum for the treatment of refractory ovarian cancer
  Gynecologic Oncology, 1981